bioatla presented phase 2 ozuriftamab vedotin clinical trial data demonstrating meaningful antitumor activity with manageable tolerability among heavily pretreated patients with squamous cell carcinoma of the head and neck (scchn) at the 2024 european society for medical oncology (esmo) annual meeting
An ongoing complete response (CR) with an overall response rate (ORR) of 32% achieved across two dosing regimens Underscores ozuriftamab...